The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. NewAmsterdam Pharma Company NV shares valued at $10,250,554 were purchased by Bain Capital Life Sciences Fun on Dec 02 ’25. At $38.33 per share, Bain Capital Life Sciences Fun acquired 267,429 shares.
Also, BCLS II Investco, LP purchased 4,500,000 shares, netting a total of over 172,485,000 in proceeds.
Before that, BCIP Life Sciences Associates, had added 32,571 shares to its account. In a trade valued at $1,248,446, the Former Affiliate bought NewAmsterdam Pharma Company NV shares for $38.33 each.
Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in late August. As of July 17, 2025, Goldman has initiated its “Neutral” rating for NAMS. Earlier on June 17, 2025, Citigroup initiated its rating. Their recommendation was “a Buy” for NAMS stock.
Analyzing NAMS Stock Performance
On last trading session, NewAmsterdam Pharma Company NV [NASDAQ: NAMS] rose 0.93% to $35.85. The stock’s lowest price that day was $35.1, but it reached a high of $36.6 in the same session. During the last five days, there has been a drop of approximately -13.51%. Over the course of the year, NewAmsterdam Pharma Company NV shares have jumped approximately 82.54%. Shares of the company reached a 52-week high of $42.00 on 11/26/25 and a 52-week low of $14.06 on 04/07/25.
Support And Resistance Levels for NewAmsterdam Pharma Company NV (NAMS)
According to the 24-hour chart, there is a support level at 35.03, which, if violated, would cause prices to drop to 34.20. In the upper region, resistance lies at 36.64. The next price resistance is at 37.42. RSI (Relative Strength Index) is 43.62 on the 14-day chart, showing neutral technical sentiment.
Is NewAmsterdam Pharma Company NV subject to short interest?
Stocks of NewAmsterdam Pharma Company NV saw a sharp steep in short interest on 2025-11-14 dropping by 38874.0 shares to 6.82 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 6.86 million shares. A decline of -0.57% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.87 of the overall float, the days-to-cover ratio (short ratio) decline to 5.87.
Which companies own the most shares of NewAmsterdam Pharma Company NV (NAMS)?
In terms of NewAmsterdam Pharma Company NV share price expectations, FactSet research, analysts set an average price target of 45 in the next 12 months, up nearly 26.69% from the previous closing price of $35.52. Analysts anticipate NewAmsterdam Pharma Company NV stock to reach 52 by 2025, with the lowest price target being 37. In spite of this, 1 analysts ranked NewAmsterdam Pharma Company NV stock as Buy at the end of 2025. On June 10, 2025, Stifel assigned a price target of “a Buy” to the stock and initiated coverage with a $44.
